References
- SchillerJHHarringtonDBelaniCPEastern Cooperative Oncology GroupComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
- TakedaMOkamotoISakaiKKawakamiHNishioKNakagawaKClinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapyAnn Oncol201223112931293622771825
- SolomonBJMokTKimDWPROFILE 1014 InvestigatorsFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
- MitsudomiTMoritaSYatabeYWest Japan Oncology GroupGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
- MaemondoMInoueAKobayashiKNorth-East Japan Study GroupGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
- FolkmanJWhat is the evidence that tumors are angiogenesis dependent?J Natl Cancer Inst1990821461688381
- SetoTHigashiyamaMFunaiHPrognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancerLung Cancer2006531919616697074
- FerraraNGerberHPLeCouterJThe biology of VEGF and its receptorsNat Med20039666967612778165
- KimKJLiBWinerJInhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature199336264238418447683111
- ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
- SandlerAGrayRPerryMCPaclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
- HilbergFRothGJKrssakMBIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacyCancer Res200868124774478218559524
- MrossKStefanicMGmehlingDPhase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumorsClin Cancer Res201016131131920028771
- OkamotoIKanedaHSatohTPhase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumorsMol Cancer Ther20109102825283320688946
- HuillardOMirOPeyromaureMSarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patientsBr J Cancer201310851034104123462722
- LarsonRADrukerBJGuilhotFIRIS (International Randomized Interferon vs STI571) Study GroupImatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyBlood200811184022402818256322
- EllisPMKaiserRZhaoYStopferPGyorffySHannaNPhase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patientsClin Cancer Res201016102881288920460487
- HannaNKaiserRSullivanRLume-lung 2: a multicenter, ran-domized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapyJ Clin Oncol201331 sul;abstr8034
- BousquetGAlexandreJLe TourneauCPhase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patientsBr J Cancer2011105111640164522027711
- ReckMKaiserRMellemgaardALUME-Lung 1 Study GroupDocetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialLancet Oncol201415214315524411639
- OkamotoIMiyazakiMTakedaMTolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancerJ Thorac Oncol201510234635225299232